Key result
Preexisting immunity to AAV, present as neutralizing antibodies in 18% of normal human subjects, completely prevented AAV-mediated gene delivery in mice, an effect that could not be overcome by transient immunosuppression.
Preexisting neutralizing antibodies to AAV limit gene delivery efficacy, but mapping specific neutralizing epitopes may enable reverse genetic engineering of AAV vectors to evade immune responses.
Answers are grounded in this paper and cite their sources.
Screening for AAV neutralizing antibodies warrants caution in gene therapy candidates; leaves open whether epitope-mapped capsids can restore efficacy in cardiovascular applications.
Recombinant adeno-associated virus type 2 (AAV) is a common vector used in human gene therapy protocols. We characterized the humoral immune response to AAV and observed that 80% of normal human subjects have anti-AAV antibodies and that 18% have neutralizing antibodies. To analyze the effect of neutralizing antibodies on AAV readministration, we attempted to deliver recombinant AAV expressing human factor IX (AAV-hFIX) intraportally into the livers of mice which had been preexposed to AAV and shown to harbor a neutralizing antibody response. While all naive control mice expressed hFIX following administration of AAV-hFIX, none of the mice with preexisting immunity expressed hFIX, even after transient immunosuppression at the time of the second administration with anti-CD4 or anti-CD40L antibodies. This suggests that preexisting immunity to AAV, as measured by a neutralizing antibody response, may limit AAV-mediated gene delivery. Using human sera in an enzyme-linked immunosorbent assay for AAV and a capsid peptide scan library to block antibody binding, we mapped seven regions of the AAV capsid containing immunogenic epitopes. Using pools of these peptides to inhibit the binding of neutralizing antibodies, we have identified a subset of six peptides which potentially reconstitute a single neutralizing epitope. This information may allow the design of reverse genetic approaches to circumvent the preexisting immunity that can be encountered in some individuals.
No takes yet. Share an insight, caveat, or question.
Москаленко et al. (2000) studied Preexisting immunity to AAV (n=50). Preexisting AAV immunity vs. Naive (no preexisting immunity) was evaluated on Expression of hFIX following AAV-hFIX administration in mice. Preexisting immunity to AAV, present as neutralizing antibodies in 18% of normal human subjects, completely prevented AAV-mediated gene delivery in mice, an effect that could not be overcome by transient immunosuppression.
Synapse has enriched 10 related papers. Consider them for comparative context: